Scribe markets its Nasdaq IPO at a $14 midpoint for ~$96M net proceeds; Scholar Rock's apitegromab awaits an FDA call on Novo Nordisk's Indiana site.
July 20, 2026 11:20 AM EDT
News Briefing
Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab
Scribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Scribe Therapeutics files for a Nasdaq IPO under ticker SCTX, testing investor appetite for early-stage biotechs still short of…
Scribe Therapeutics prices its Nasdaq IPO (SCTX), kicking off a wave of six biotechs expected to go public in the coming weeks.
The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go…
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other…
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Cartesian’s $150M financing; Editas Medicine’s money moves
